WHAT IS CLAIMED IS:

1. Use of an effective amount of onvansertib in the manufacture of a medicament for the treatment of a KRAS-mutated metastatic colorectal cancer in combination with bevacizumab and a chemotherapy containing fluorouracil; wherein a patient having a KRAS-mutated metastatic colorectal cancer is selected for the treatment, the patient not having received any prior treatment for the metastatic colorectal cancer and not having received any prior treatment with bevacizumab; and wherein onvansertib is to be administered in multiple doses and bevacizumab is to be administered in multiple doses to the patient during a treatment cycle.

2. The use of claim 1, wherein the patient has not received a prior chemotherapy for the metastatic colorectal cancer.

3. The use of claim 2, wherein the prior chemotherapy comprises a treatment using FOLFIRI, abiraterone, FOLFOX, an anti-EGFR agent, a KRAS-directed inhibitor, gemcitabine, abraxane, nanoliposomal irinotecan, 5-fluorouuracil (5-FU), FOLFIRINOX, FOLFOXIRI, or a combination thereof.

4. The use of claim 1, wherein onvansertib is to be administered for at least four days and bevacizumab is to be administered weekly or biweekly in the treatment cycle; wherein the treatment cycle is about 21 to 28 days; and wherein the patient is to undergo at least two treatment cycles.

5. The use of claim 1, wherein onvansertib and bevacizumab are to be administered to the patient simultaneously or sequentially.

6. The use of claim 1, wherein the administration of onvansertib is oral administration, and the administration of bevacizumab is intravenous administration or oral administration.

7. The use of claim 1, wherein onvansertib is to be administered at 12 mg/m^2 – 90 mg/m^2.

8. The use of claim 1, wherein bevacizumab is to be administered at 1 mg/kg – 20 mg/kg.

9. The use of claim 1, wherein onvansertib and bevacizumab are to be administered to the patient in combination with FOLFIRI.

10. The use of claim 1, wherein one or more additional cancer therapeutics or therapies is/are to be administered to the patient.

11. The use of claim 10, wherein the one or more additional cancer therapeutics or therapies comprise FOLFIRI, abiraterone, FOLFOX, an anti-EGFR agent, a KRAS directed inhibitor, gemcitabine, abraxane, nanoliposomal irinotecan, 5-FU, or a combination thereof.

12. The use of claim 1, wherein the cancer status of the patient is determined.

13. The use of claim 1, wherein onvansertib and bevacizumab synergistically improves objective response rate (ORR) and/or progression free survival (PFS) in the patient.

14. The use of claim 13, wherein the patient achieves about 2-fold, 3-fold, 4-fold or 5-fold higher ORR, compared to patients who have received prior bevacizumab treatment.

15. The use of claim 13, wherein the patient achieves about 2-fold higher PFS, compared to patients who have received prior bevacizumab treatment.

16. The use of claim 1, wherein the patient is human.